Literature DB >> 22415870

A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.

Tomoyuki Sugimoto1, Takashi Sozu, Toshimitsu Hamasaki.   

Abstract

The clinical efficacy of a new treatment may often be better evaluated by two or more co-primary endpoints. Recently, in pharmaceutical drug development, there has been increasing discussion regarding establishing statistically significant favorable results on more than one endpoint in comparisons between treatments, which is referred to as a problem of multiple co-primary endpoints. Several methods have been proposed for calculating the sample size required to design a trial with multiple co-primary correlated endpoints. However, because these methods require users to have considerable mathematical sophistication and knowledge of programming techniques, their application and spread may be restricted in practice. To improve the convenience of these methods, in this paper, we provide a useful formula with accompanying numerical tables for sample size calculations to design clinical trials with two treatments, where the efficacy of a new treatment is demonstrated on continuous co-primary endpoints. In addition, we provide some examples to illustrate the sample size calculations made using the formula. Using the formula and the tables, which can be read according to the patterns of correlations and effect size ratios expected in multiple co-primary endpoints, makes it convenient to evaluate the required sample size promptly.
Copyright © 2012 John Wiley & Sons, Ltd.

Mesh:

Year:  2012        PMID: 22415870     DOI: 10.1002/pst.505

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  15 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Authors:  Toshimitsu Hamasaki; Koko Asakura; Scott R Evans; Tomoyuki Sugimoto; Takashi Sozu
Journal:  Stat Biopharm Res       Date:  2015       Impact factor: 1.452

3.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

4.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

5.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

6.  Sizing clinical trials when comparing bivariate time-to-event outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2017-01-24       Impact factor: 2.373

7.  Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.

Authors:  Yuki Ando; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Tomoyuki Sugimoto; Takashi Sozu; Yuko Ohno
Journal:  Stat Biopharm Res       Date:  2015-06-24       Impact factor: 1.452

8.  Sample size calculations for continuous outcomes in clinical nutrition.

Authors:  Christian Ritz; Mette Frahm Olsen; Benedikte Grenov; Henrik Friis
Journal:  Eur J Clin Nutr       Date:  2022-07-08       Impact factor: 4.016

9.  Pharmacological Modulation of Ischemic-Reperfusion Injury during Pringle Maneuver in Hepatic Surgery. A Prospective Randomized Pilot Study.

Authors:  Matteo Donadon; Andrea Forastieri Molinari; Francesco Corazzi; Laura Rocchi; Paola Zito; Matteo Cimino; Guido Costa; Ferdinando Raimondi; Guido Torzilli
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

10.  Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Authors:  Toshimitsu Hamasaki; Tomoyuki Sugimoto; Scott Evans; Takashi Sozu
Journal:  Pharm Stat       Date:  2012-10-19       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.